LONDON – Alkermes Inc. is acquiring the drug delivery arm of Elan plc in a cash and shares deal valued at $960 million. Of that Elan will receive $500 million cash, with the balance coming in the form of 31.9 million shares. (BioWorld International)

Shares in Wilex AG rose almost 20 percent Monday on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million. (BioWorld International)